Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
| ▸ | SCN1A | P35498 | 1/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.56 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.56 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAD52 | P43351 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16055131 | 0.88 | HSD17B2 (0.55) | CYP1A2LMNACYP3A4MAOACYP2D6 | |
| SCHEMBL6114016 | 0.87 | NPC1 (0.73) | CYP1A2LMNACYP3A4MAOACYP2D6 | |
| SCHEMBL1612538 | 0.87 | HSD17B2 (0.69) | CYP1A2LMNACYP3A4MAOACYP2D6 | |
| SCHEMBL223446 | 0.87 | HSD17B10 (0.55) | CYP1A2CYP2D6TSHRSLC6A2SCN1A | |
| SCHEMBL11336624 | 0.86 | TSHR (0.50) | CYP1A2LMNACYP3A4MAOACYP2D6 | |
| SCHEMBL1011945 | 0.85 | HSD17B2 (0.61) | CYP1A2LMNACYP3A4MAOATSHR | |
| SCHEMBL5981995 | 0.85 | HSD17B10 (0.75) | CYP1A2LMNACYP3A4CYP2D6TSHR | |
| SCHEMBL14304165 | 0.83 | CYP2D6 (0.82) | CYP1A2LMNACYP3A4MAOACYP2D6 | |
| SCHEMBL18369795 | 0.83 | CREBBP (0.76) | CYP1A2CYP3A4TSHRHSD17B10NPC1 | |
| SCHEMBL670450 | 0.83 | HSD17B2 (0.59) | CYP1A2LMNACYP3A4MAOATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376452-A1 | 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors and Methods of Use Thereof | ENANTA PHARM INC (US) | 2025-12-11 | — | — | US | disclosed |
| US-12384753-B2 | 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250154157-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR TREATING A ERK5-MEDIATED DISEASE | CANCER RESEARCH TECH LTD (GB) | 2025-05-15 | — | — | US | disclosed |
| EP-4479400-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR TREATING A ERK5-MEDIATED DISEASE | Cancer Research Technology Limited (GB) | 2024-12-25 | — | — | EP | disclosed |
| CN-119053604-A | Heterocyclic compounds for the treatment of ERK5 mediated diseases | 癌症研究技术有限公司 | 2024-11-29 | — | — | CN | disclosed |
| EP-4387603-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | Enanta Pharmaceuticals, Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| CN-118103038-A | 17 Beta-hydroxysteroid dehydrogenase 13 inhibitors and methods of use thereof | 英安塔制药有限公司 | 2024-05-28 | — | — | CN | disclosed |
| WO-2023156791-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR TREATING A ERK5-MEDIATED DISEASE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023156791-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR TREATING A ERK5-MEDIATED DISEASE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-08-24 | — | — | WO | disclosed |
| US-20230143250-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20160060273-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-03-03 | — | — | US | disclosed |
| WO-2016028391-A2 | SPIROPYRROLIDINES AS MDM2 INHIBITORS | HUDSON BIOPHARMA INC. (US) | 2016-02-25 | — | — | WO | disclosed |
| EP-2970331-A1 | SPIRO AZETIDINE ISOXAZOLE DERIVATIVES AND THEIR USE AS SSTR5 ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2016-01-20 | — | — | EP | disclosed |
| WO-2015129927-A1 | HETEROCYCLIC COMPOUNDS | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2015-09-03 | — | — | WO | disclosed |
| WO-2015129927-A1 | HETEROCYCLIC COMPOUNDS | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2015-09-03 | — | — | WO | disclosed |
| WO-2014142363-A1 | SPIRO AZETIDINE ISOXAZOLE DERIVATIVES AND THEIR USE AS SSTR5 ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-18 | — | — | WO | disclosed |
| US-8742110-B2 | Spiroxazolidinone compounds | MERCK SHARP & DOHME CORP. (US) | 2014-06-03 | — | — | US | disclosed |
| EP-2605658-A1 | SPIROXAZOLIDINONE COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2013-06-26 | — | — | EP | disclosed |
| US-20130131042-A1 | SPIROXAZOLIDINONE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2013-05-23 | — | — | US | disclosed |
| WO-2012024183-A1 | SPIROXAZOLIDINONE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143250-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | HSD17B1, HSD17B13, HSD17B3 | CYP1A2 83/4885LMNA 2111/4885CYP3A4 228/4885 |
| US-20160060273-A1 | HETEROCYCLIC COMPOUND | SSTR5, SSTR1, SSTR2 | CYP1A2 3133/4885LMNA 4589/4885CYP3A4 3350/4885 |
| US-20250376452-A1 | 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors and Methods of Use Thereof | HSD17B1, HSD17B13, HSD17B3 | CYP1A2 83/4885LMNA 2111/4885CYP3A4 228/4885 |
| US-12384753-B2 | 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof | HSD17B1, HSD17B13, HSD17B3 | CYP1A2 83/4885LMNA 2111/4885CYP3A4 228/4885 |
| US-20130131042-A1 | SPIROXAZOLIDINONE COMPOUNDS | SSTR5, SSTR2, SSTR4 | CYP1A2 1190/4885LMNA 746/4885CYP3A4 2866/4885 |
| US-20250154157-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR TREATING A ERK5-MEDIATED DISEASE | MAP3K5, MAPK1, MAP3K20 | CYP1A2 1431/4885LMNA 2790/4885CYP3A4 2933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.